Capricor Inc.
Clinical trials sponsored by Capricor Inc., explained in plain language.
-
Hope for duchenne: new drug shows promise in Long-Term trial
Disease control OngoingThis study is for people with Duchenne muscular dystrophy who already completed the HOPE-2 trial. It tests the long-term safety and effectiveness of a drug called deramiocel, given as an IV infusion every three months for up to five years. The goal is to see if the drug can help …
Phase: PHASE2 • Sponsor: Capricor Inc. • Aim: Disease control
Last updated May 17, 2026 10:38 UTC
-
Experimental cell therapy aims to slow muscle loss in duchenne MD
Disease control OngoingThis phase 3 trial tests whether a cell therapy called deramiocel (CAP-1002) can slow muscle decline in boys and young men with Duchenne muscular dystrophy (DMD). About 106 participants receive either the therapy or a placebo every 3 months for a year, then all can receive the th…
Phase: PHASE3 • Sponsor: Capricor Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC